Answers are grounded in this paper and cite their sources.
Chronic proton pump inhibitor (PPI) use is a major health economics issue in the UK. NICE recommends that patients with nonulcer dyspepsia and gastro-oesophageal reflux disease should receive the lowest dose of medication necessary to control symptoms.
No takes yet. Share an insight, caveat, or question.
Evans et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: